Search

Search Results

• DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA

  Ali Taher

  e2018066

  2018-11-01

  https://doi.org/10.4084/mjhid.2018.066

  3091

  PDF: 1624

  HTML: 360

• IRON CHELATION THERAPY IN THALASSEMIA SYNDROMES

  Paolo Cianciulli

  e2009034

  1315

  PDF: 633

  HTML: 2331

• MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY

  Emanuele Angelucci, Silvana Anna Maria Urru, Federica Pilo, Alberto Piperno

  e2017021

  2017-03-01

  https://doi.org/10.4084/mjhid.2017.021

  3614

  PDF: 1328

  HTML: 2075

  Fig.1: 229

  Fig. 2: 225

• TRANSIENT ELASTOGRAPHY (TE) IS A USEFUL TOOL FOR ASSESSING THE RESPONSE OF LIVER IRON CHELATION IN SICKLE CELL DISEASE PATIENTS

  SOPHIA DELICOU

  e2018049

  2018-09-01

  https://doi.org/10.4084/mjhid.2018.049

  1619

  PDF: 851

  HTML: 225

• LONG-TERM EFFECTIVENESS, SAFETY, AND TOLERABILITY OF TWICE-DAILY DOSING WITH DEFERASIROX IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSEMIAS UNRESPONSIVE TO STANDARD ONCE-DAILY DOSING

  Jassada Buaboonnam, Chayamon Takpradit, Vip Viprakasit, Nattee Narkbunnam, Nassawee Vathana, Kamon Phuakpet, Kleebsabai Sanpakit, Bunchoo Pongtanakul

  e2021065

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.065

  1228

  PDF: 460

  HTML: 185

• THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA

  adel abd elhaleim hagag

  e2013065

  2013-11-04

  https://doi.org/10.4084/mjhid.2013.065

  2793

  PDF: 859

  HTML: 15023

  Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 334

• IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS

  Elena Maria Elli, Angelo Belotti, Andrea Aroldi, Matteo Parma, Pietro Pioltelli, Enrico Maria Pogliani

  e2014042

  2014-05-30

  https://doi.org/10.4084/mjhid.2014.042

  2200

  PDF: 1181

  HTML: 2016

• A Young Adult with Unintentional Acute Parenteral Iron intoxication Treated with Oral Chelation: The Use of Liver Ferriscan.

  Vincenzo De Sanctis

  e2017008

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.008

  3190

  PDF: 1045

  HTML: 1661

• ECONOMIC EVALUATION OF CHELATION REGIMENS FOR ?--THALASSEMIA MAJOR: A SYSTEMATIC REVIEW

  Jialian Li

  e2019036

  2019-06-24

  https://doi.org/10.4084/mjhid.2019.036

  2057

  PDF: 1481

  HTML: 235

• JADENU® SUBSTITUTING EXJADE® IN IRON OVERLOADED ?- THALASSEMIA MAJOR (BTM) PATIENTS: A PRELIMINARY REPORT OF THE EFFECTS ON THE TOLERABILITY, SERUM FERRITIN LEVEL, LIVER IRON CONCENTRATION AND BIOCHEMICAL PROFILES

  Vincenzo De Sanctis

  e2018064

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.064

  2723

  PDF: 1244

  HTML: 441

• THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone

  George J Kontoghiorghes, Marios Kleanthous, Christina N. Kontoghiorghe

  e2020011

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.011

  2493

  PDF: 1626

  HTML: 696

• BETA THALASSEMIA MAJOR IN A DEVELOPING COUNTRY: EPIDEMIOLOGICAL, CLINICAL AND EVOLUTIONARY ASPECT

  Mohamed Bejaoui, Naouel Guirat

  e2013002

  2013-01-01

  https://doi.org/10.4084/mjhid.2013.002

  1693

  PDF: 921

  HTML: 2523

• LONGITUDINAL STUDY ON LIVER FUNCTIONS IN PATIENTS WITH THALASSEMIA MAJOR BEFORE AND AFTER DEFERASIROX (DFX) THERAPY

  Ashraf Tawfik Soliman, Mohamed Yassin, Fawzia AlYafei, Lolwa Al-Naimi, Noora Almarri, Aml Sabt, Vincenzo De Sanctis

  e2014025

  2014-04-06

  https://doi.org/10.4084/mjhid.2014.025

  2320

  PDF: 2189

  HTML: 2490

• Rhino-Orbital-Cerebral Mucormycosis after Allogeneic Hematopoietic Stem Cell Transplantation and Isavuconazole Therapeutic Drug Monitoring during Intestinal Graft versus Host Disease

  Giacomo Andreani, Gianluca Fadda, Dario Gned, Matteo Dragani, Giovanni Cavallo, Valentina Monticone, Alessandro Morotti, Marco De Gobbi, Angelo Guerrasio, Antonio D'Avolio, Daniela Cilloni

  e2019061

  2019-10-30

  https://doi.org/10.4084/mjhid.2019.061

  1484

  PDF: 1124

  HTML: 232

• PREVENTION OF ? THALASSEMIA IN NORTHERN ISRAEL - A COST-BENEFIT ANALYSIS.

  Ariel Koren, Lora Profeta, Luci Zalman, Haya Palmor, Carina Levin, Ronit Bril Zamir, Stavit Shalev, Orna Blondheim

  e2014012

  2014-02-17

  https://doi.org/10.4084/mjhid.2014.012

  3093

  PDF: 1289

  HTML: 11855

• The COST-UTILITY ANALYSIS OF FOUR CHELATION REGIMENS FOR ?-THALASSEMIA MAJOR: A CHINESE PERSPECTIVE

  Jialian Li

  e2020029

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.029

  1925

  PDF: 994

  HTML: 346

• NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES

  Francesco D'Alò, Mariangela Greco, Marianna Criscuolo, Maria Teresa Voso

  e2010021

  2010-08-11

  https://doi.org/10.4084/mjhid.2010.021

  2043

  PDF: 1374

  HTML: 799

• ASSOCİATİON BETWEEN IRON OVERLOAD AND GLUCOSE METABOLİSM İN CHİLDREN AND YOUTH WİTH TRANSFUSİON-DEPENDENT BETA THALASSEMİA: THE ROLE OF CHELATİON THERAPY

  Deniz Guven, Dr. İncefidan, Dr. Kazanci, Dr. Ozlem Kara

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.017

  734

  PDF: 653

  HTML: 131

• GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload

  Vincenzo De Sanctis, Ashraf Soliman, Shahina Daar, Ploutarchos Tzoulis , Salvatore Di Maio, Christos Kattamis

  e2023006

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.006

  4016

  PDF: 1158

  HTML: 466

• CARDIAC FUNCTION AND IRON CHELATION IN THALASSEMIA MAJOR AND INTERMEDIA: A REVIEW OF THE UNDERLYING PATHOPHYSIOLOGY AND APPROACH TO CHELATION MANAGEMENT

  Athanasios Aessopos, Vasilios Berdoukas

  e2009002

  2009-07-18

  1633

  PDF: 492

  HTML: 1562

• SEVERE LIVER IRON CONCENTRATIONS (LIC) IN 24 PATIENTS WITH ?-THALASSEMIA MAJOR: CORRELATIONS WITH SERUM FERRITIN, LIVER ENZYMES AND ENDOCRINE COMPLICATIONS

  Vincenzo De Sanctis

  e2018062

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.062

  2768

  PDF: 1427

  HTML: 367

• ZYGOMYCOSIS IN IMMUNOCOMPROMISED NON-HAEMATOLOGICAL PATIENTS

  George Petrikkos, Miranda Drogari-Apiranthitou

  e2011012

  2011-03-14

  https://doi.org/10.4084/mjhid.2011.012

  2947

  PDF: 989

  HTML: 7492

• EARLY PREDICTORS OF RENAL DYSFUNCTION IN ?-THALASSEMIA MAJOR AND INTERMEDIA PATIENTS

  Azza A.G. Tantawy, Nagham El Bablawy, Amira A. M Adly, Fatma S E Ebeid

  e2014057

  2004-09-01

  https://doi.org/10.4084/mjhid.2014.057

  2007

  PDF: 969

  HTML: 3890

• HEALTH-RELATED QUALITY OF LIFE IN THAI CHILDREN WITH THALASSEMIA AS EVALUATED BY PEDSQL AND EQ-5D-Y: A SINGLE CENTER EXPERIENCE

  Pacharapan Surapolchai, Phakatip Sinlapamongkolkul

  e2020036

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.036

  1594

  PDF: 1176

  HTML: 377

• FASTING PLASMA GLUCOSE LEVELS WITHIN THE HIGH NORMAL RANGE ARE ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF FUTURE DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β THALASSEMIA: A DECADE-LONG MULTICENTER RETROSPECTIVE ANALYSIS Higher normal fasting plasma glucose and glucose dysregulation in β- thalassemia

  Vincenzo De Sanctis, Forough Saki, Mehran Karimi, Mohammad Faranoush, Ihab Elhakim, Ashraf T Soliman, Shahina Daar, Ploutarchos Tzoulis

  e2025072

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.072

  760

  PDF: 285

  Html: 36

• GROWTH AND ENDOCRINE FUNCTION IN TUNISIAN THALASSEMIA MAJOR PATIENTS

  Naouel GUIRAT

  e2018031

  2018-05-01

  https://doi.org/10.4084/mjhid.2018.031

  4663

  PDF: 1052

  HTML: 476

  TABLE: 204

  FIGURES: 273

• THE DIAGNOSTIC VALUE OF PULSED WAVE TISSUE DOPPLER IMAGING IN ASYMPTOMATIC BETA- THALASSEMIA MAJOR CHILDREN AND YOUNG ADULTS ; RELATION TO CHEMICAL BIOMARKERS OF LEFT VENTRICULAR FUNCTION AND IRON OVERLOAD .

  Seham Ragab

  e2015051

  2015-08-24

  https://doi.org/10.4084/mjhid.2015.051

  1449

  PDF: 896

  HTML: 1440

  Untitled: 202

• LIVER IRON CONTENT (LIC) IN ADULTS WITH NON-TRANSFUSION DEPENDENT SICKLE CELL DISEASE (NT-SCD). CORRELATION WITH SERUM FERRITIN AND LIVER ENZYMES CONCENTRATIONS

  Vincenzo De Sanctis

  e2017037

  2017-06-20

  https://doi.org/10.4084/mjhid.2017.037

  4005

  PDF: 1006

  HTML: 1214

• ASSOCIATION OF VDBP RS4701 VARIANT, BUT NOT VDR/RXR-? OVER-EXPRESSION WITH BONE MINERAL DENSITY IN PEDIATRIC ?-THALASSEMIA PATIENTS Vitamin D metabolic axis and BMD in ?-thalassemia

  Shaimaa Sahmoud, Mostafa S. Ibrahim, Eman A. Toraih, Noha Kamel, Manal Fawzy, Samar Elfiky

  e2020037

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.037

  1347

  PDF: 759

  HTML: 286

• Does splenectomy influence the development of Hypothyroidism in Transfusion Dependent Thalassemia Patients? A retrospective study. Splenectomy in Hypothyroidism of TDT patients

  Christos KATTAMIS, Myrto Skafida, Christalena Sofocleous, Antonis Kattamis

  e2019064

  2019-10-30

  https://doi.org/10.4084/mjhid.2019.064

  1289

  PDF: 983

  HTML: 336

• INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY

  Giuseppe Leone, Livio Pagano

  e2018039

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.039

  4389

  PDF: 1478

  HTML: 720

• STUDY OF SERUM HAPTOGLOBIN LEVEL AND ITS RELATION TO ERYTHROPOIETIC ACTIVITY IN BETA THALASSEMIA CHILDREN .

  Seham Ragab, Manal A. Safan, Eman A. Badr

  e2015019

  2015-02-12

  https://doi.org/10.4084/mjhid.2015.019

  2297

  PDF: 1191

  HTML: 2603

  Study of serum haptoglobin level in thalassemia: 376

  Figures: 201

• A MULTICENTER ICET-A STUDY ON AGE AT MENARCHE AND MENSTRUAL CYCLES IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA (TDT) WHO STARTED EARLY CHELATION THERAPY WITH DIFFERENT CHELATING AGENTS. Age at menarche and menstrual cycles in patients with transfusion-dependent thalassemia.

  SALVATORE DI MAIO, VINCENZO DE SANCTIS, PIERLUIGI MARZUILLO, CHRISTOS KATTAMIS, SHAHINA DAAR, MEHERAN KARIMI, SAKI FOROUGH, ATANAS BANKEV, VALERIA KALEVA, SOTEROULA CHRISTOU, CARMELO FORTUGNO, POLYXENI DELAPORTA, ASHRAF T SOLIMAN , PLOUTARCHOS TZOULIS

  e2023058

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.058

  842

  PDF: 559

  HTML: 142

• VASCULAR ENDOTHELIAL GROWTH FACTOR IN CHILDREN WITH THALASSEMIA MAJOR PDF

  sameh samir fahmey, Hassan Naguib, sanna Abdelshafy, rasha Alashry

  e2013044

  2013-06-05

  https://doi.org/10.4084/mjhid.2013.044

  1362

  PDF: 891

  HTML: 1075

  Figure 1 the correlation between frequency of blood transfusion and serum vascular endothelial growth factor (VEGF).: 201

• CORRELATION OF TRANSIENT ELASTOGRAPHY WITH LIVER IRON CONCENTRATION, AND SERUM FERRITIN LEVELS IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA MAJOR PATIENTS FROM OMAN

  Hammad Khan, Vinodh Panjwani, Sara Al Rahbi, Abubakr Eltigani , Rizwan Qureshi, Khaleeq Unnisa, Najmus Sehar, Alok Mittal, Anil Pathare

  e2023048

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.048

  1196

  PDF: 723

  HTML: 248

• THE ICET-A RECOMMENDATIONS FOR THE DIAGNOSIS AND MANAGEMENT OF DISTURBANCES OF GLUCOSE HOMEOSTASIS IN THALASSEMIA MAJOR PATIENTS

  Vincenzo De Sanctis

  e2016058

  2016-10-25

  https://doi.org/10.4084/mjhid.2016.058

  4298

  PDF: 1245

  HTML: 1320

• POST-LOAD PLASMA GLUCOSE INCREASE (PG-GAP) AS A RISK FACTOR FOR DEVELOPING DYSGLYCEMIA IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (Β-TDT): RETROSPECTIVE ANALYSIS OVER 8 YEARS Post load plasma glucose increase and the risk of glucose dysregulation in thalassemia

  Vincenzo De Sanctis, Mohammad Faranoush, Efthymia Vlachaki, Theodora- Maria Venou, Ashraf T Soliman, Shahina Daar, Ploutarchos Tzoulis, Christos Kattamis

  e2025069

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.069

  558

  PDF: 272

  HTML: 163

• Luspatercept Treatment in a β-Thalassemia Patient with Pulmonary Arterial Hypertension: A Case Report

  beibei yang, dongmei liu, changyu yang, Yali zhou, Guiping Liao, jian huang, Yingying Li, yinjiang tang, xiaolin yin

  e2025059

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.059

  1212

  PDF: 619

  Html: 168

• DOES INSULIN LIKE GROWTH FACTOR-1 (IGF-1) DEFICIENCY HAVE A “PROTECTIVE” ROLE IN THE DEVELOPMENT OF DIABETIC RETINOPATHY IN THALASSEMIA MAJOR PATIENTS?

  Vincenzo De Sanctis

  e2015038

  2015-05-20

  https://doi.org/10.4084/mjhid.2015.038

  2024

  PDF: 953

  HTML: 5133

• CAN WE PREDICT INCIPIENT DIABETES MELLITUS IN PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA (β-TDT) REFERRED WITH A HISTORY OF PREDIABETES? Risk factors for incipient diabetes in thalassemia

  Vincenzo De Sanctis, Ashraf Soliman, Shahina Daar, Ploutarchos Tzoulis, Christos Kattamis

  e2024005

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.005

  1132

  PDF: 1378

  HTML: 168

• THE ROLE OF THE CAROTID DOPPLER EXAMINATION IN THE EVALUATION OF ATHEROSCLEROTIC CHANGES IN BETA THALASSEMIA PATIENTS

  Gehan Lotfy Abdel Hakeem, hoda Abdel kereem Abdel Samei, Ashraf mohamed El Shereif, Ahlam mohamed ismail

  e2015023

  2015-02-17

  https://doi.org/10.4084/mjhid.2015.023

  2233

  PDF: 1014

  HTML: 3066

  Untitled: 233

• The Splenectomy Paradox in Thalassemia: Reduced Transfusion Requirements vs. Accelerated Hepatic Fibrogenesis

  Padmapani Padeniya, Dileepa Ediriweera, Madunil Niriella, Arjuna De Silva, Dulani Kottahachchi, Anuja Premawardhena

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.023

  595

  PDF: 476

  HTML: 98

• The IMPACT OF SUPEROXIDE DISMUTASE GENETIC POLYMORPHISM (SOD2 VAL16ALA) AND SUPEROXIDE DISMUTASE LEVEL ON DISEASE SEVERITY IN A COHORT OF EGYPTIAN SICKLE CELL DISEASE PATIENTS IN EGYPT SOD and SCD in Egypt

  Mervat Khorshied, Iman A, Shaheen, Yasmeen M.M Selim, Asmaa O. Elshahawy, Ilham Youssry

  e2022037

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.037

  1178

  PDF: 626

  HTML: 497

• EVALUATION OF GLUTATHIONE-S-TRANSFERASE P1 POLYMORPHISM AND ITS RELATION TO BONE MINERAL DENSITY IN EGYPTIAN CHILDREN AND ADOLESCENTS WITH BETA- THALASSEMIA MAJOR

  Seham Ragab

  e2016004

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.004

  3966

  PDF: 875

  HTML: 2460

  Figures: 187

• LIVER DISEASE & SICKLE CELL DISEASE: AUTOIMMUNE HEPATITIS MORE THAN A COINCIDENCE; A SYSTEMATIC LITERATURE REVIEW.

  Kelvin Lynch, Andrea Mega, Andrea Piccin, Massimo Daves, Helen Fogarty

  e2023060

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.060

  2418

  PDF: 2340

  HTML: 376

• HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA AND SICKLE CELL DISEASE: EXPERIENCE OF MEDITERRANEAN INSTITUTE OF HEMATOLOGY IN A MULTI-ETHNIC POPULATION.

  Marco Marziali, Antonella Isgrò, Javid Gaziev, Guido Lucarelli

  e2009027

  2009-12-26

  1775

  PDF: 740

  HTML: 2973

• Concordance Rate of Fasting Plasma Glucose (PG) and 2-hour PG post Oral Glucose Tolerance Test (OGTT) in Patients with new diagnosis of Thalassemia-Related Diabetes Mellitus (Th-RDM):Implications for Clinical Practice OGTT concordance rate in thalassemia major

  Vincenzo De Sanctis, Mohammad Faranoush, Shahina Daar, Ihab Elhakim, Ashraf T Soliman, Forough Saki, Mehran Karimi, Ploutarchos Tzoulis

  e2026011

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.011

  763

  PDF: 574

  Html: 137

• EPIDEMIOLOGY OF INVASIVE FUNGAL INFECTIONS IN THE MEDITERRANEAN AREA

  Ulrike Binder, Cornelia Lass-Flörl

  e2011016

  2011-03-30

  https://doi.org/10.4084/mjhid.2011.016

  2315

  PDF: 1011

  HTML: 4977

• EFFICACY AND SAFETY OF SINOPHARM VACCINE FOR SARS-COV-2 AND BREAKTHROUGH INFECTIONS IN IRANIAN PATIENTS WITH HEMOGLOBINOPATHIES: A PRELIMINARY REPORT Sinopharm Vaccination in Iranian Patients with Hemoglobinopathies

  Mehran Karimi, Tahereh Zarei, Sezaneh Haghpanah , Azita Azarkeiva, Maryam Naderi , Sara Matin , Asghar Bazrafshan , Zohreh Zahedi , Afshan Shirkavand , Parisa pishdad, Vincenzo De Sanctis

  e2022026

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.026

  1765

  PDF: 756

  HTML: 238

• ACQUIRED HYPOGONADOTROPIC HYPOGONADISM (AHH) IN THALASSAEMIA MAJOR PATIENTS: AN UNDERDIAGNOSED CONDITION?

  Vincenzo De Sanctis

  e2016001

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.001

  5395

  PDF: 1331

  HTML: 3640